Minnesota. She is an expert in obtaining blood samples from pancreatic cancer patients and controlling for age, sex, and other parameters. So we had a very rigorous study. The extreme care with which we matched patients and controls is part of the strength of our work,” he said.
The next step in their work is to use the test in more and more patients, specifically those at higher risk for pancreatic cancer.
“It will let us assess whether our biomarker test will allow us to detect cancer even before it is stage 1,” said Zaret — “stage negative 1,” so to speak.
“Our big goal is to be able to detect pancreatic cancer before it’s at the 13 percent survival rate, which is where a stage 1 diagnosis is now.”
If that succeeds, doctors would be able to identify more patients earlier, raising hopes of achieving higher survival rates for pancreatic cancer down the road.
Comentarios recientes